Obstetrics & Gynaecology

Tranexamic acid does not prevent haemorrhage-related events in Caesarean section

Yesterday

Among women with multiple pregnancies, prophylactic treatment with tranexamic acid does not appear to reduce the incidence of blood loss-related events following caesarean delivery, a study has shown.

Maintenance niraparib a boon in advanced ovarian cancer

Jairia Dela Cruz, 2 days ago

Use of niraparib in the maintenance setting appears to minimize the risk of progression in advanced ovarian cancer patients, with surgical timing having little to no effect on the drug’s efficacy, as shown in a post hoc analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 study.

Occupational lifting, pushing put women at risk of pelvic organ prolapse

19 Jun 2022

Physically demanding jobs may be hazardous to women, with a recent study reporting that occupational load-bearing contributes to an increase in the risk of developing symptomatic pelvic organ prolapse during midlife.

How effective are contraceptive counseling, provision interventions for women?

16 Jun 2022

Contraceptive counseling and provision of services beyond usual care are both effective at improving contraceptive use without increasing sexually transmitted infections (STIs) or reducing condom use, results of a systematic review and meta-analysis have shown.

Management of recurrent implantation failure during the COVID-19 pandemic

Dr. Ameet Patki, Dr. Prakash Mayandi, 22 Mar 2022

Recurrent implantation failure (RIF) refers to the failure to achieve a clinical pregnancy after three in vitro fertilization (IVF) attempts with at least four good-quality embryos. RIF leaves couples frustrated and desperate for answers and is challenging for clinicians to handle, compounded by the impact of the COVID-19 pandemic restrictions. Two experts, Dr Ameet Patki, Medical Director of Fertility Associates Mumbai and Hon Assoc Prof at KJ Somaiya Medical College & Hospital, India, and Dr Prakash Mayandi, Metro IVF Fertility Centre, Kuala Lumpur, Malaysia, weigh in with their views on managing RIF during the COVID-19 pandemic.

The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib

Dr. Wong Seng Weng, Dr. Lee Guek Eng, 19 Mar 2021

In Singapore, advanced breast cancer (aBC) is the leading cause of cancer death in women 30–49 years of age. For premenopausal women diagnosed with hormone receptor (HR)-positive, HER2-negative BC, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors provide new hope. Currently, ribociclib is the only CDK4/6 inhibitor studied in the first-line setting for premenopausal women with HR+/HER2- aBC, in the phase III MONALEESA-7 trial. Two experts, Dr Wong Seng Weng, Medical Director & Consultant Medical Oncologist at The Cancer Centre, Paragon Medical & Mount Elizabeth Novena Specialist Centre, and Dr Lee Guek Eng, Senior Consultant & Specialist in Medical Oncology at Icon Cancer Centre and Program Director of the Young Women Cancer Program, weigh in with their views on managing premenopausal women with aBC.

Acute diarrhoea is the second leading cause of death in children aged younger than 5 years, accounting for approximately 1.9 million deaths worldwide each year; however, diarrhoea is a preventable and treatable condition. In Malaysia, acute gastroenteritis accounts for about 1.3% of all deaths in children aged younger than 5 years annually. Diarrhoea is defined as the passage of three or more loose or watery stools within 24 hours, and it may be clinically categorised as either acute watery diarrhoea (AWD), acute bloody diarrhoea, persistent diarrhoea or diarrhoea with severe malnutrition.

01 Sep 2020

Acute diarrhoea is the second leading cause of deathin children aged younger than 5 years, accounting forapproximately 1.9 million deaths worldwide each year;however, diarrhoea is a preventable and treatable condition.In Malaysia, acute gastroenteritis accounts for about 1.3%of all deaths in children aged younger than 5 years annually.Diarrhoea is defined as the passage of three or more looseor watery stools within 24 hours, and it may be clinicallycategorised as either acute watery diarrhoea (AWD), acutebloody diarrhoea, persistent diarrhoea or diarrhoea withsevere malnutrition.

Expert consensus: Patient profile should guide antihistamine choice in primary care setting

10 Dec 2019

Oral H₁-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.

Linzagolix benefits Hb levels, mood, QoL

Roshini Claire Anthony, 26 May 2022

The use of the oral GnRH antagonist linzagolix in patients with heavy menstrual bleeding (HMB) due to uterine fibroids induced multiple benefits including improved haemoglobin (Hb) levels, health-related quality of life (HRQoL), and mood, analysis of the PRIMROSE 1 and 2 trials showed.

Fezolinetant reduces hot flashes in menopausal women

Elaine Soliven, 21 May 2022

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

Once-daily, low-dose elagolix reduces HMB in premenopausal women with uterine fibroids

Elaine Soliven, 20 May 2022

Once-daily (QD) administration of low-dose elagolix 150 mg led to significantly reduced heavy menstrual bleeding (HMB) in premenopausal women with uterine fibroids, according to a study presented at ACOG 2022.

Relugolix combo improves uterine fibroid symptoms regardless of fibroid location

Stephen Padilla, 17 May 2022

Combination therapy with relugolix (once daily relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) leads to improvement in heavy menstrual bleeding (HMB) and in other uterine fibroid (UF)-related symptoms independent of the location of the largest fibroid, results of a recent study have shown.

Pelvic floor dysfunction in women warrants further attention

Audrey Abella, 17 May 2022

There appears to be a dearth of evidence on the management of nonrelaxing pelvic floor dysfunction (PFD), a debilitating condition characterized by tension of the pelvic floor muscles that frequently leads to pelvic pain, according to data presented at ACOG 2022.